title: Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
abstract: OBJECTIVE
  Intestinal metaplasia (IM) is more often found in patients with Helicobacter pylori (H pylori) infection, while eradication of H pylori results in significant reduction in the severity and activity of chronic gastritis. We aimed to determine in patients with unsuccessful eradication of H pylori the role of various proton pump inhibitors (PPIs) having different mechanisms in the resolution of IM.
  
  
  METHODS
  We confirmed endoscopically and pathohistologically (Sydney classification) the IM in 335 patients with gastritis before and after medication for eradication of H pylori (Maastricht Protocol 2002). H pylori infection was determined by using histology, urease test and culture. Control endoscopy and histology were done after 30 d and thereafter (within 1 year). Unsuccessful eradication was considered if only one of the three tests (histology, urease and culture) was negative after therapy protocol. We used omeprazole, pantoprazole, lansoprazole in therapy protocols (in combination with two antibiotics).
  
  
  RESULTS
  We found no significant difference in resolution of IM by using different PPI between the groups of eradicated and noneradicated patients (P<0.4821 and P<0.4388, respectively).
  
  
  CONCLUSIONS
  There is no significant difference in resolution of intestinal metaplasia by different proton pump inhibitors.
authors.affiliation: Division of Gastroenterology, Department of Medicine, Sveti Duh General Hospital, Sveti Duh 64, HR-10000 Zagreb, Croatia.
authors.forename: Marinko
authors.initials: M
authors.lastname: Marusic
authors.forename: Zarko
authors.initials: Z
authors.lastname: Babic
authors.forename: Mirjana
authors.initials: M
authors.lastname: Nesanovic
authors.forename: Mira
authors.initials: M
authors.lastname: Lucijanic-Mlinac
authors.forename: Vesna
authors.initials: V
authors.lastname: Stajcar
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001562:Benzimidazoles / Q000627:therapeutic use; D002908:Chronic Disease; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology*; D016480:Helicobacter pylori; D006801:Humans; D007422:Intestines / Q000473:pathology*; D064747:Lansoprazole; D008297:Male; D008679:Metaplasia; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D013454:Sulfoxides / Q000627:therapeutic use
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D064747:Lansoprazole; D000077402:Pantoprazole; D009853:Omeprazole